These data will be submitted to regulatory authorities in the U.S. by F2G and in Europe and Asia by Shionogi. F2G anticipates ...
Approval based on Phase 3 data showing unprecedented functional cure rates compared to standard of care – – Six-month ...
Hengrui Pharma continues to expand the clinical value of established products and advance its innovative pipeline, while ...
Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces that further to its announcement on September ...
Insilico reached the first R&D milestone using its proprietary Pharma.AI platform, triggering an undisclosed milestone ...
Approval based on phase III data showing unprecedented functional cure rates compared to standard of care ...
Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical ...
RxSight, Inc., today announced that it will report financial results for the third quarter of 2026 after the market close on ...
(“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of ...
CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management ...
A strong crossover raise can suggest that a company has “reached a level of maturity” and could go public soon, according to ...
Bioxodes SA, a clinical stage biopharmaceutical company developing novel therapies for the prevention and treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results